While future work will be required to test the therapeutic potential of each of these antigens, as the antigenicity of CIITA-glioblastoma tumors is greatly enhanced, we propose that vaccination approaches with CIITA-expressing GBM cells could be effective, potentially by sensitizing the tumors to other immunotherapies. Here, CIITA is linked to glioblastoma.